TY  - GEN
AU  - Lincoff,A M
AU  - Mark,D B
AU  - Tcheng,J E
AU  - Califf,R M
AU  - Bala,M V
AU  - Anderson,K M
AU  - Davidson-Ray,L
AU  - Knight,J D
AU  - Cabot,C F
AU  - Topol,E J
TI  - Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade
SN  - 1524-4539
PY  - 2001///0104
KW  - Abciximab
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - economics
KW  - Drug Therapy, Combination
KW  - Health Care Costs
KW  - Hemorrhage
KW  - prevention & control
KW  - Heparin
KW  - administration & dosage
KW  - Humans
KW  - Immunoglobulin Fab Fragments
KW  - Middle Aged
KW  - Myocardial Ischemia
KW  - Myocardial Revascularization
KW  - Platelet Aggregation Inhibitors
KW  - Platelet Glycoprotein GPIb-IX Complex
KW  - antagonists & inhibitors
KW  - Platelet Membrane Glycoproteins
KW  - Postoperative Complications
KW  - Prospective Studies
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1161/01.cir.102.24.2923
ER  -